Kodiak AI completes its first autonomous trucking demonstrations outside the Sun Belt on Interstate 70 in Ohio and Indiana, as the Level 4 autonomous trucking market accelerates toward a projected $7.8 billion by 2036.
Real-world data from the first year-long implantable CGM arrives as over-the-counter glucose biosensors pivot toward AI-driven wellness coaching, splitting the market between clinical precision and consumer accessibility.
The three largest Open RAN operators are scaling deployments in 2026, with AT&T past 50% of its Nokia-to-Ericsson radio swap and targeting 70% open-capable traffic by year-end.
Two bipartisan Senate bills would create a VA Office of Novel Therapeutics and fund psychedelic research centers, while states enact their own laws and Phase 3 trials advance.
A decade after the first lab-grown brain models, organoid research is crossing from laboratory curiosity to clinical reality, prompting calls for governance frameworks to match the pace of science.
The CFPB's landmark open banking rule missed its April 1 compliance deadline after a court injunction and agency reconsideration, but major banks are forging private data-sharing deals that may shape the market before regulators act.
SIG Network ships the stable release of its migration tool two weeks before Ingress-NGINX was archived, expanding annotation coverage tenfold and introducing behavioral equivalence testing against live clusters.
The FDA has accepted Ultragenyx's resubmitted BLA for UX111, a one-time gene therapy for the fatal childhood disease Sanfilippo syndrome Type A, with a decision expected by September 19, 2026.
Salt Security and KushoAI release dueling reports on the same day showing API security has become the critical blind spot of the agentic AI era, with nearly all attacks now originating from authenticated sources.
JPMorgan commits to 60,000 tons of carbon removal credits from Graphyte, while Microsoft secures 626,000 tonnes from Canada's first Indigenous-owned BECCS project, as corporate buyers race to underwrite the next generation of carbon removal infrastructure.
Full results from Novo Nordisk's EVOKE and EVOKE+ trials, published in The Lancet, show oral semaglutide had no effect on cognitive decline over two years despite reducing key cerebrospinal fluid markers of neuroinflammation and tau pathology by roughly 10 percent.
Minnesota PUC approves Xcel Energy's $430 million Capacity*Connect program to deploy up to 200 MW of utility-owned batteries, sparking a national debate over who should control distributed energy storage.